BlackRock Inc. increased its position in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 19.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,309 shares of the specialty pharmaceutical company’s stock after buying an additional 3,104 shares during the quarter. BlackRock Inc.’s holdings in Kalvista Pharmaceuticals were worth $427,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. EAM Investors LLC purchased a new position in Kalvista Pharmaceuticals during the 3rd quarter worth $926,000. Acuta Capital Partners LLC purchased a new position in Kalvista Pharmaceuticals during the 3rd quarter worth $2,849,000. Wells Fargo & Company MN purchased a new position in Kalvista Pharmaceuticals during the 3rd quarter worth $598,000. Finally, Wedge Capital Management L L P NC purchased a new position in Kalvista Pharmaceuticals during the 3rd quarter worth $1,492,000. Institutional investors and hedge funds own 73.75% of the company’s stock.
A number of research firms have recently weighed in on KALV. Zacks Investment Research raised shares of Kalvista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th. ValuEngine raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. BidaskClub cut shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 18th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price target on shares of Kalvista Pharmaceuticals in a research note on Friday, December 14th. Finally, Jefferies Financial Group began coverage on shares of Kalvista Pharmaceuticals in a research note on Tuesday, October 30th. They set a “buy” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $26.00.
NASDAQ:KALV opened at $19.07 on Tuesday. Kalvista Pharmaceuticals Inc has a fifty-two week low of $7.73 and a fifty-two week high of $25.57. The firm has a market cap of $330.04 million, a PE ratio of -12.46 and a beta of 2.38.
Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Friday, December 14th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.24. Kalvista Pharmaceuticals had a negative net margin of 84.47% and a negative return on equity of 29.46%. The business had revenue of $5.59 million for the quarter, compared to analysts’ expectations of $3.70 million. Research analysts predict that Kalvista Pharmaceuticals Inc will post -1.78 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://dakotafinancialnews.com/2019/02/12/blackrock-inc-boosts-position-in-kalvista-pharmaceuticals-inc-kalv.html.
Kalvista Pharmaceuticals Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
See Also: How dollar cost averaging works
Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kalvista Pharmaceuticals Inc (NASDAQ:KALV).
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.